摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

tert-Butyl 5-isopropyl-1H-indazole-1-carboxylate

中文名称
——
中文别名
——
英文名称
tert-Butyl 5-isopropyl-1H-indazole-1-carboxylate
英文别名
tert-butyl 5-propan-2-ylindazole-1-carboxylate
tert-Butyl 5-isopropyl-1H-indazole-1-carboxylate化学式
CAS
——
化学式
C15H20N2O2
mdl
——
分子量
260.33
InChiKey
XDAUEQRNVHPVMJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4
  • 重原子数:
    19
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.47
  • 拓扑面积:
    44.1
  • 氢给体数:
    0
  • 氢受体数:
    3

文献信息

  • 2,4-disubstituted pyrimidines useful as kinase inhibitors
    申请人:Celgene CAR LLC
    公开号:US10010548B2
    公开(公告)日:2018-07-03
    The present invention provides 2,4-disubstituted pyrimidine compounds useful as kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same.
    本发明提供了可用作激酶抑制剂的 2,4-二取代嘧啶化合物、其药学上可接受的组合物以及使用方法。
  • Substituted 2,4-diaminopyrimidines as kinase inhibitors
    申请人:Celgene CAR LLC
    公开号:US10828300B2
    公开(公告)日:2020-11-10
    The present invention provides 2,4-diaminopyrimidines, and/or pharmaceutically acceptable compositions thereof, as kinase inhibitors.
    本发明提供了作为激酶抑制剂的 2,4-二氨基嘧啶和/或其药学上可接受的组合物。
  • RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AS WELL AS PREPARATION METHOD AND USE THEREOF
    申请人:Beijing Tide Pharmaceutical Co., Ltd.
    公开号:EP3421465B1
    公开(公告)日:2022-10-26
  • HETEROARYL COMPOUNDS AND USES THEREOF
    申请人:Celgene Avilomics Research, Inc.
    公开号:US20170100397A1
    公开(公告)日:2017-04-13
    The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
  • METHOD FOR TREATING FATTY LIVER DISEASE AND/OR STEATOHEPATITIS
    申请人:BEIJING TIDE PHARMACEUTICAL CO., LTD.
    公开号:US20220378743A1
    公开(公告)日:2022-12-01
    The present invention falls within the field of biological medicine, and specifically relates to a method for preventing, alleviating and/or treating fatty liver disease and/or steatohepatitis. The method comprises administering, to an individual in need thereof, an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, an ester, a stereoisomer, a polymorph, a solvate, an N-oxide, an isotopically labeled compound, a metabolite or a prodrug thereof.
查看更多